Lercanidipine Biogaran

Lercanidipine Hydrochloride, the active ingredient in Lercanidipine Biogaran, is a calcium channel blocker presented as an oral tablet for oral use. It is indicated for the management of hypertension in adult patients. GNH USA supplies Lercanidipine Biogaran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lercanidipine is a dihydropyridine calcium‑channel blocker used in the treatment of elevated blood pressure.

Hypertension: lowers elevated blood pressure, helping to reduce the risk of cardiovascular complications.

Lercanidipine may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Flushing: sensation of warmth and redness, usually resolves without intervention. - Peripheral edema: swelling of the ankles or lower legs. - Dizziness or light‑headedness, especially after standing. - Nausea: occasional mild gastrointestinal upset. - Tachycardia: slight increase in heart rate.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, tongue, or throat requiring urgent care. - Severe hypotension: marked drop in blood pressure leading to fainting. - Hepatic dysfunction: abnormal liver enzymes or hepatitis. - Allergic reactions: rash, pruritus, or anaphylaxis. - Myocardial infarction: rare occurrence of heart attack. - Cardiac arrhythmias: irregular heart rhythms.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications.

Blood pressure monitoring: measure BP before starting treatment and periodically thereafter. Renal impairment: use with caution in patients with severe renal dysfunction. Hepatic impairment: dose adjustment may be required in moderate to severe liver disease. Concomitant CYP3A4 inhibitors: may increase plasma levels, monitor for adverse effects. Store at room temperature: keep in the original container, protect from moisture and direct light.

Lercanidipine can interact with several drug classes, influencing its efficacy and safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may cause significant increase in lercanidipine exposure. - Grapefruit juice: can markedly increase plasma concentration. - Other antihypertensives (e.g., ACE inhibitors, diuretics): risk of excessive hypotension.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect. - Beta‑blockers: additive effect on blood pressure and heart rate. - Lithium: may increase lithium serum levels, requiring monitoring.